. "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . "A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years"@en . . . "10"^^ . . . "NCT01352793" . . . . . . . . . . . . "A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years"@en . "2014-09-01T00:00:00Z"^^ . . . "25"^^ . . . . . . . . . . . "A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years"@en . "ensayu cl\u00EDnicu"@ast . . "2012-11-01T00:00:00Z"^^ . . . . . "5715"^^ . . . . . . . "A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Safety And Tolerability Of A Meningococcal Serogroup B Bivalent Recombinant Lipoprotein (rlp2086) Vaccine Given In Healthy Subjects Aged Greater Than Or Equal To 10 To Less Than 26 Years"@en . . . . "klinisch onderzoek"@nl . . . . . "clinical trial"@en . . . . . . . .